National People's Congress representative Yu Qingming: Sinopharm's new crown virus vaccine production capacity can reach more than 1 billion doses this year

Yu Qingming, a representative of the National People's Congress and chairman of Sinopharm Group, said on the 3rd that Sinopharm's China Bio-New Coronavirus inactivated vaccine has been put into large-scale production, and the production capacity can reach more than 1 billion doses this year.

At present, 4 new coronavirus vaccines in my country have been conditionally approved by the State Food and Drug Administration, and 5 technical routes have been approved for clinical trials of 16 vaccine varieties in emergency, of which 6 vaccine varieties have undergone phase III clinical trials.

Information released by the Ministry of Science and Technology shows that in addition to inactivated vaccines, the other four technical routes that my country is advancing simultaneously include recombinant protein vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines, and nucleic acid vaccines.